Can a patient take Celexa (citalopram) together with nortriptyline?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Celexa and Nortriptyline Be Taken Together?

Yes, a patient can take Celexa (citalopram) and nortriptyline together, but this combination requires careful monitoring due to the risk of serotonin syndrome and potential QT interval prolongation. 1, 2

Key Safety Considerations

Serotonin Syndrome Risk

The combination of citalopram (an SSRI) with nortriptyline (a tricyclic antidepressant with serotonergic properties) creates a moderate risk for serotonin syndrome. Caution should be exercised when combining two or more non-MAOI serotonergic drugs, including SSRIs and TCAs. 1

The approach to safe combination therapy includes:

  • Start the second serotonergic drug at a low dose
  • Increase the dose slowly
  • Monitor closely for symptoms, especially in the first 24 to 48 hours after dosage changes 1

Watch for serotonin syndrome symptoms:

  • Mental status changes (confusion, agitation, anxiety)
  • Neuromuscular hyperactivity (tremors, clonus, hyperreflexia, muscle rigidity)
  • Autonomic hyperactivity (hypertension, tachycardia, diaphoresis, vomiting, diarrhea)
  • Advanced symptoms: fever, seizures, arrhythmias, unconsciousness 1

QT Prolongation Concerns

Both citalopram and nortriptyline can prolong the QT interval, creating additive cardiac risk. 3, 4

Specific considerations:

  • Citalopram carries higher QT prolongation risk among SSRIs (highest with citalopram and escitalopram, negligible with paroxetine and sertraline) 3
  • Citalopram may cause QT prolongation associated with Torsade de Pointes, ventricular tachycardia, and sudden death at daily doses exceeding 40 mg/day 1
  • TCAs including nortriptyline are associated with increased cardiac arrest risk (OR = 1.69) 4
  • SSRIs are associated with cardiac arrest risk (OR = 1.21) 4

When combining these medications, consider baseline and follow-up ECGs, especially if:

  • Patient has other QT-prolonging risk factors
  • Patient is elderly (>60 years)
  • Patient has structural heart disease
  • Patient is taking other QT-prolonging medications
  • Patient has electrolyte disturbances 3, 4

Pharmacokinetic Interactions

Citalopram has minimal effect on CYP450 isoenzymes compared with other SSRIs and has a lower propensity for drug interactions. 1 Research evidence supports this: a case study demonstrated that adding citalopram 40-60 mg/day to amitriptyline 75 mg/day had no effect on tricyclic plasma levels 5. This suggests citalopram is less likely than fluoxetine or paroxetine to increase nortriptyline levels through CYP2D6 inhibition.

However, one case report documented severe sedation when melatonin was added to a regimen including both citalopram and nortriptyline, suggesting potential for pharmacokinetic interactions under certain circumstances 6.

Clinical Evidence Supporting Combination Use

Research demonstrates that combined amitriptyline and citalopram therapy can be beneficial for patients who don't respond to monotherapy. 7 In a study of patients with comorbid depression, migraine, and tension-type headache, those who failed monotherapy with either drug showed substantial improvement when both were combined, without producing major side effects such as serotonergic syndrome 7.

Additionally, switching between nortriptyline and escitalopram (a closely related SSRI) has been shown effective for patients experiencing side effects or non-response, with significant MADRS score improvements in both switching directions 8.

Practical Management Algorithm

When prescribing this combination:

  1. Assess baseline cardiac risk:

    • Obtain ECG if patient >60 years, has cardiac disease, takes other QT-prolonging drugs, or has electrolyte abnormalities 3, 4
    • Check electrolytes (potassium, magnesium) and renal function 3
  2. Start conservatively:

    • Begin with low doses of both medications
    • If adding one to the other, start the second drug at the lowest available dose 1
  3. Titrate slowly:

    • Increase doses gradually at 1-2 week intervals for citalopram 1
    • Monitor therapeutic nortriptyline levels (50-150 ng/mL) 9
  4. Monitor intensively during initiation:

    • Watch for serotonin syndrome symptoms in first 24-48 hours after each dose change 1
    • Educate patient and family about warning signs 2
    • Monitor blood pressure, heart rate, mental status
  5. Maintain appropriate dosing limits:

    • Keep citalopram ≤40 mg/day (≤20 mg/day if >60 years old) 1, 4
    • Keep nortriptyline ≤40 mg/day in elderly patients 9
  6. Ongoing monitoring:

    • Regular assessment for autonomic side effects (more common with nortriptyline) 10
    • Periodic ECG monitoring if risk factors present 3, 4
    • Monitor for falls risk, especially in elderly patients 11

Common Pitfalls to Avoid

  • Don't combine with MAOIs - absolute contraindication with 14-day washout period required 2
  • Don't ignore cardiac risk factors - elderly patients and those with heart disease require closer monitoring 3, 4
  • Don't use high doses of citalopram - stay within FDA-recommended limits to minimize QT risk 1, 4
  • Don't overlook drug interactions - be cautious with other serotonergic drugs (tramadol, triptans, linezolid) 2
  • Don't forget bleeding risk - both drugs increase bleeding risk, especially with NSAIDs, aspirin, or warfarin 1, 2

Alternative Considerations

If cardiac risk is prohibitive or serotonin syndrome concerns are high, consider alternative SSRIs with lower QT risk (sertraline, paroxetine) or alternative antidepressants with different mechanisms 3, 12. However, the evidence suggests this combination can be used safely with appropriate precautions and monitoring.

References

Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Research

Melatonin Interaction Resulting in Severe Sedation.

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.